GlobeNewswire (Tue, 8:29AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
969 people get SGYP articles and Market Currents by email alert.
Get email alerts on SGYP »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (Apr 16, 2013)
-
GlobeNewswire (Apr 10, 2013)
-
GlobeNewswire (Apr 9, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
GlobeNewswire (Feb 22, 2013)
-
GlobeNewswire (Feb 11, 2013)
-
GlobeNewswire (Feb 7, 2013)
-
GlobeNewswire (Jan 3, 2013)
-
GlobeNewswire (Dec 27, 2012)
To learn more about Seeking Alpha Pro, click here.
-
Synergy Pharma: Plecanatide Topline Data To Serve As Catalyst For StockVineet Dutta • Wed, Oct 24, 2012
-
Synergy Pharmaceuticals May Be Ready To RollVFC's Stock House • Tue, May 22, 2012
-
Key Appointment Marks Another Win For Synergy PharmaceuticalsVFC's Stock House • Thu, May 3, 2012
-
Stock Watch Thursday, 15 NovemberVFC's Stock House • Thu, Nov 15, 2012
There are no Transcripts on SGYP.
-
GlobeNewswire (Tue, 8:29AM)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (Apr 16, 2013)
-
GlobeNewswire (Apr 10, 2013)
-
GlobeNewswire (Apr 9, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
GlobeNewswire (Feb 22, 2013)
-
GlobeNewswire (Feb 11, 2013)
-
GlobeNewswire (Feb 7, 2013)
-
GlobeNewswire (Jan 3, 2013)
-
at MarketWatch.com (Jan 2, 2013)
-
GlobeNewswire (Dec 27, 2012)
-
GlobeNewswire (Nov 21, 2012)
-
GlobeNewswire (Nov 13, 2012)
-
GlobeNewswire (Nov 9, 2012)
SGYP vs. ETF Alternatives
Company Description
Currently, there's no company description for SGYP.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 6:07 PM Synergy Pharmaceuticals (SGYP): Q1 EPS of -$0.26 misses by $0.10. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, April 23, 8:30 AM Ironwood Pharmaceuticals (IRWD) sinks 13.3% premarket after saying sales of Linzess — the IBS drug the company markets with Forest Labs (FRX) — were $4.5M for Q1 versus expectations of $11-13M. Credit Suisse and Wedbush previously said early evidence suggested demand for the drug was strong. Irina Rivkind at Cantor says Synergy's (SGYP) investigational candidate plecanatide has the potential to achieve revenue parity with Linzess. Comment! [On the Move, Healthcare]
- Tuesday, April 16, 2:37 PM Synergy Pharmaceuticals (SGYP +3%) gains today after closing its 16.375M public offering at $5.50 per share, just a 1% discount from yesterday's close. Net proceeds from the sale came to $84.5M, for which the company plans to use to fund R&D activities, including further clinical development of plecanatide and its other pipeline programs, as well as for other general corporate purposes. Comment! [Healthcare, On the Move]
- Thursday, April 11, 1:26 PM Synergy Pharmaceuticals (SGYP -11%) takes a big hit after pricing its public offering of 16.375M shares at $5.46, an 8.5% discount to yesterday's close. The sale generated round $90.1M in gross proceeds. Comment! [On the Move, Healthcare]
-
Thursday, April 11, 12:49 PM
Midday top 10 gainers: ACAD +55%. RNIN +26%. RAD +18%. ZUMZ +15%. MEA +13%. BIOL +12%. MGT +12%. PBTH +12%. MPAC +11%. TVL +11%.
Midday top 10 losers: LEDS -17%. FTNT -14%. ROYL -14%. NTIC -16%. HXM -11%. CREG -11%. PRMW -10%. GNVC -10%. SGYP -10%. OCZ -10%. Comment! [On the Move] -
Thursday, April 11, 9:10 AM
Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%. Comment! [On the Move] -
Wednesday, April 10, 9:10 AM
Premarket gainers: ADTN +8%. PPHM +6%. NJ +6%.
Losers: TITN -18%. HMA -14%. SGYP -13%. RLGY -6%. GRA -5%. Comment! [On the Move] -
Tuesday, April 9, 5:56 PM
After-hours top gainers, as of 5:15 p.m.: ACTS +8%. PSUN +6%. PZE +5%. PSMT +4%. NAVB +3%.
After-hours top losers: SGYP -12%. HMA -11%. SEAC -10%. RLGY -7%. THC -5%. Comment! [On the Move] - Tuesday, April 9, 5:13 PM Synergy Pharmaceuticals (SGYP) announces a $90M secondary offering, with an overallotment authorization totalling $103.5M of its common stock if the underwriters exercise their over-allotment option in full. Shares -14% AH. Comment! [Healthcare, On the Move]
- Tuesday, April 9, 11:44 AM Synergy Pharmaceuticals (SGYP +10.3%) soars on heavy volume after Cantor Fitzgerald raises its price target on the shares to $15 from $12. Irina Rivkind says the company's lead investigational drug plecanatide can "achieve revenue parity" with Ironwood (IRWD -0.5%) and Forest Laboratories' (FRX -0.2%) Linzess, an FDA approved treatment for constipation. Comment! [Healthcare, On the Move]
- Monday, March 18, 5:36 PM Synergy Pharmaceuticals (SGYP): Q4 EPS of -$0.18 misses by $0.02. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Wednesday, January 2, 9:10 AM
Premarket gainers: ZIP +47.94%. POL +18.71%. SGYP +16.92%. MCP +9%. JRCC +8.41%. PAL +7.69%. KWK +7.69%. ZGNX +7.52%. PPHM +6.82%. ONTY +6.77%.
Losers: ABT -50%. 6 Comments - Wednesday, January 2, 8:27 AM Synergy Pharmaceuticals (SGYP) +18.4% after the company says that its plecanatide oral treatment for chronic constipation due to an unknown cause met the primary and secondary goals of a Phase IIb/III study. Chronic constipation is the most common digestive complaint in the world, with about 15%, or 45M people, suffering in the U.S. (PR) Comment! [Healthcare, On the Move]
- Friday, December 28, 2012, 1:33 PM Synergy Pharmaceuticals (SGYP -2.2%) slips after saying it has completed a Phase I clinical trials of SP-333, a treatment for ulcerative colitis and other GI diseases. According to the results, SP-333 exhibited potent anti-inflammatory activity in animal studies, which the company believes can provide a new way to treat UC patients with mild to moderate disease. The company plans to start a multi-dose escalation trial in January. 3 Comments [Healthcare, On the Move]
- Thursday, December 27, 2012, 2:09 PM Synergy Pharmaceuticals (SGYP +5.3%) moves up after saying its commenced Phase IIb clinical trials of plecanatide, a treatment for patients with constipation-predominant irritable bowel syndrome. The trial is being conducted at 70 sites in the U.S. and includes 350 patients. Parexel International (PRXL -2%) is the contract research organization for the trial. Comment! [Healthcare, On the Move]
- Thursday, November 15, 2012, 12:45 PM Midday top 10 gainers: RCON +91%. BXG +55%. CALI +45%. SGOC +44%. BGMD +22%. MEET +21%. ACRX +15%. SZYM +13%. DANG +12%. SGYP +11%. Midday top 10 Losers: TZYM -75%. FFEX -48%. TRIT -38%. ATEA -35%. SB -34%. VELT -34%. NAII -25%. OSIS -24%. UTSI -23%. DMND -22%. 1 Comment [On the Move]
-
- View all 1 replies
-
WheelsComingOff: Ya, that was pretty messed up. I was waiting for it to go over $7, as that looks great on the charts, then to get hammered after hours?
-
Red Acre Investments
$SGYP adjourns annual meeting until 1/14 = more time to trade CLSP prior to merger vote. - View all 0 replies
-
Red Acre Investments
$SGYP positive trial results. http://bit.ly/Vtoei1 Wepredicted data would be out Jan 2 here: http://bit.ly/V6LOBp - View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
WheelsComingOff: Ya, that was pretty messed up. I was waiting for it to go over $7, as that looks great on the charts, then to get hammered after hours?
-
Red Acre Investments
$SGYP starts IBS-C trial - bullish for upcoming data: http://bit.ly/V6LOBp Get Ahead of the Curve by signing up! - View all 3 replies
-
-
-
Shane Blackmon
$SGYP FV-100 looks interesting, 1 pill per day, rather than 12 pills with Valtrex. Valtrex had 339M pounds of sales in 2011 for $GSK. - View all 2 replies
-
-
Shane Blackmon: ha, i dont have the symbol for British pounds on my computer... or else i just don't know how to do it.
-
Scott Matusow
What I hear on $SGYP is company in Negotiations with large pharma for their diarrhea treatment - View all 2 replies
-
-
-
Scott Matusow
My article on $SGYP @ Synergy Pharma: Vying For A Piece Of The 20 Billion Dollar Gastrointestinal Disorder Market - View all 16 replies
-
raktim81: Scott, when did you notice that the hedge play is in? I just sold my small position for the same price I bought it for. -
Scott Matusow: when the stock has huge buying interest the other day, hits 4.95, continued ask buying and computer trading takes it back down to the po.
-
- View all 4 replies
-
-
Scott Matusow: prob not the next week although 5 i doable. id say up to 3 months out in my opinon, but you never know, i didnt think ISR would do that.
-
Scott Matusow
I have several articles due out tomorrow; $SGYP, $ATRS both on Seeking Alpha and Biomedreports.com - View all 6 replies
-
-
JMo25: in my opinion, of course, through all Scott's research he has provided.
-
- View all 12 replies
-
-
Scott Matusow: yes, I did DANDISK, at $4.31 depends Mais how far it gaps. if too far, wait and see if it back fills a little bit.





